Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Potential applications<br />
Establishment of human serum,<br />
urine and tissue biorepositories<br />
(WP1)<br />
➝<br />
Discovery and evaluation of novel<br />
Pca markers using innovative<br />
masss pectrometry tools (WP2)<br />
Validation and clinical<br />
implementation of Pca markers<br />
(WP4)<br />
P-Mark will evaluate the clinical value of recently developed<br />
promising Pca markers and of novel Pca markers. If a marker<br />
meets the defi ned P-Mark marker criteria (improved sensitivity<br />
and specifi city over current markers for diagnosis or<br />
prognosis; indicative for early detection, over-treatment,<br />
risk for progression or therapy resistance; clinically relevant<br />
target in relation to tumour biology; reliable and cost-effi -<br />
ciently determinable in non-invasively obtained specimens;<br />
stable component in specimen), it will be developed further<br />
for the validation in a monocentre or multi-centre setting.<br />
In addition, the marker will be off ered to commercial enterprises<br />
for commercialisation. Validation will lead to guidelines<br />
for cost-effi cient strategies for detection and treatment as<br />
well as recommendations for marker application, that have<br />
to be discussed in the public domain of related European<br />
professional societies. Validated markers will be off ered to<br />
the principal investigators of ongoing screening studies in<br />
Europe for implementation in the study. Taken the duration<br />
of P-Mark into consideration (three years), clinical marker<br />
implementation will continue beyond this project.<br />
Evaluation of six recently<br />
developed promising Pca<br />
markers (WP3)<br />
Expected results:<br />
• New validated prostate cancer markers<br />
• Novel prostate cancer markers ready for validation<br />
• Identifi ed risk groups in European population<br />
• Guidelines for prostate cancer detection and therapy<br />
EARLY DETECTION, DIAGNOSIS AND PROGNOSIS<br />
➝ ➝<br />
➝<br />
➝<br />
Identifi cation risk groups (ERSPC)<br />
(WP5)<br />
Coordinator<br />
Chris H. Bangma<br />
Dept. of Urology<br />
Erasmus MC<br />
Rotterdam, The Netherlands<br />
h.j.vanalphen@erasmusmc.nl<br />
Partners<br />
Hans Lilige<br />
Dept. of Laboratory Medicine<br />
Division of Clinical Chemistry<br />
Wallenberg Laboratory, University Hospital<br />
Malmö<br />
Malmö, Sweden<br />
Jack Schalken<br />
Dept. of Experimental Urology<br />
University of Nijmegen<br />
Nijmegen, The Netherlands<br />
Freddie Hamdy<br />
Dept. of Urology<br />
University of Sheffield<br />
Sheffield, United Kingdom<br />
Project number<br />
LSHC-CT-2004-503011<br />
EC contribution<br />
€ 3 480 764<br />
Duration<br />
48 months<br />
Starting date<br />
01/11/2004<br />
Instrument<br />
STREP<br />
Project website<br />
www.p-mark.org<br />
Ulf-Hakan Stenman<br />
Dept. of Clinical Chemistry<br />
Helsinki University<br />
Central Hospital<br />
Helsinki, Finland<br />
Kim S. Pettersson<br />
Dept. of Biotechnology<br />
University of Turku<br />
Turku, Finland<br />
Rainer Bischoff<br />
Centre for Pharmacy, Analysis of<br />
Biomacromolecules<br />
University of Groningen<br />
Groningen, The Netherlands<br />
Harri Takalo<br />
Innotrac Diagnostics OY<br />
Turku, Finland<br />
Olle Nilsson<br />
Fujirebio Diagnostics AB<br />
Gödenborg, Sweden<br />
147
Change language